Methotrexate (MTX) is the widely agreed upon first-choice second-line agent to treat juvenile idiopathic arthritis (JIA), up to 75% of JIA patients in recent registries have used MTX at some time ...

to evaluate if intravenous infusion affects signs and symptoms of oligoarticular or polyarticular juvenile idiopathic arthritis (JIA) and improve quality of life in suffering children aged 2 ...

Conditions like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic ... The two most common types—osteoarthritis and rheumatoid arthritis—have distinct causes and treatment ...

Background: Observational studies examining the association between oral health and juvenile idiopathic arthritis (JIA) among children and adolescents have reported inconsistent findings.